Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co.,...
Ridger Achieves xFusion's FusionXpark™ (NVIDIA GB10-Based) Compatibility Certification, Delivering Industry-Leading Mobility for Practical AI Deployment
The fusion of AI-native storage and computing overcomes the final barrier to enterprise AI adoption, delivering unprecedented mobility, performance, and simplicity for data-sensitive industries. SINGAPORE, Feb. 10, 2026 /PRNewswire/ -- Ridger, the...